4:21 PM
Nov 08, 2018
 |  BC Extra  |  Financial News

Buysiders brush off midterms

Although drug pricing reform is one of the few bipartisan issues that a divided Congress might be able to agree upon, key biotech and pharma indexes have largely shrugged off the midterm results in a sign that it’s business as usual for biopharma investors.

After rising 1-3% on Wednesday, biotech indexes gave back some of their initial gains. Since Tuesday's close, the NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD